E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Alveolar Soft Part Sarcoma |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10001883 |
E.1.2 | Term | Alveolar soft part sarcomas |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10001883 |
E.1.2 | Term | Alveolar soft part sarcomas |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to measure the percentage change in the size of patient's tumours after 24 weeks of treatment (or at the time of disease progression if this is sooner) in patients taking cediranib, compared to those taking a placebo. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are: • To measure the response rate of patients after 24 weeks of treatment (this is the percentage of patients having a complete response to treatment or a partial response to treatment. The different types of 'response' described are defined by specific criteria in a standard document called RECIST v1.1). Also, to measure the best response seen and the best reduction in tumour size for each patient. • To measure progression-free survival (this is the length of time the patient's cancer does not get worse); also to measure the percentage of patients who are alive and progression-free at 12 months (this is the percentage of patients who at 12 months are still alive and their cancer has not got worse). • To measure the overall survival of patients, which measures how long each patient survives, regardless of the stage of their disease. • To evaluate how safe and how well tolerated cediranib is in patients with ASPS
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria 1. Histologically confirmed diagnosis of ASPS (central confirmation not required at study entry) 2. Age 16 years and older 3. Availability of archived tissue blocks to enable confirmation of t(X;17) translocation 4. ECOG Performance Status of 0-1 5. Life expectancy of >12 weeks 6. Progressive disease as defined by RECIST v1.1 within 6 months prior to randomisation 7. Measurable metastatic disease using RECISTv1.1, i.e. at least one lesion 10 mm in diameter (15 mm in short axis for nodal lesions) assessable by CT (or MRI for brain metastases). 8. Patients with brain metastases are permitted provided disease is controlled with a stable dose of corticosteroid and/or non-enzyme inducing anticonvulsant 9. The capacity to understand the patient information sheet and ability to provide written informed consent 10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures 11. Able to swallow and retain oral medication |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria 1. Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count ≤1.5 x 109/L or platelet count ≤100 x 109/L 2. Serum bilirubin ≥ 1.5 x ULN (unless Gilbert’s syndrome) 3. ALT or AST ≥ 2.5 x ULN. If liver metastases are present, ALT or AST > 5 x ULN 4. Serum creatinine > 1.5 x ULN or a creatinine clearance (calculated or measured) of ≤ 50mL/min 5. Greater than +1 proteinuria unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio < 1.5 6. History of significant gastrointestinal impairment, as judged by the Investigator, that would significantly affect the absorption of cediranib 7. Patients with a history of poorly controlled hypertension with resting blood pressure >150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy 8. Any evidence of severe or uncontrolled co-morbidities e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, or active and uncontrolled infection 9. Evidence of prolonged QTc >480 msec (using Bazetts correction, for which the formula is: QTc = QT/√RR) or history of familial long QT syndrome 10. Significant recent haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks) 11. Major thoracic or abdominal surgery in the 14 days prior to entry into the study, or a surgical incision that is not fully healed 12. Pregnant or breast-feeding women; women of childbearing potential with a positive pregnancy test prior to receiving study medication; women the intention of pregnancy during study treatment; women of child bearing potential unwilling to have a urine or serum pregnancy test prior to study entry (even if surgically sterilised) 13. Men and women of childbearing potential unwilling to use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilisation) for the duration of the study and should continue such precautions for 2 weeks after receiving the last study treatment 14. History of anticancer (including investigational, non-registered) treatment in the four weeks prior to first dose of cediranib, with the exception of palliative radiotherapy for symptom control 15. Previous treatment with cediranib 16. Known hypersensitivity to any excipient of cediranib 17. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of the primary cancer of interest from a target lesion 18. Other concomitant anti-cancer therapy (including LHRH agonists) except steroids 19. Recent history of thrombosis 20. Patients with brain metastases if they are symptomatic requiring increasing steroids in the previous six weeks to study entry or those with evidence of recent and/or active bleeding, or those causing uncontrolled seizures |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of this study is to evaluate the efficacy of cediranib in the treatment of ASPS by measuring the percentage change in tumour size from randomisation to week 24 (or progression if sooner) compared to treatment with placebo. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints are 24 weeks RECISTv1.1 response rate, best RECISTv1.1 response, best reduction (%) in tumour size, progression-free survival rate, percentage alive and progression-free at 12 months; overall survival rate and the safety and tolerability profile of cediranib in patients with ASPS. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the interventional period of the trial is defined as 30 days after the last trial participant receives the last dose of the investigational medicinal product. However patients will continue to be followed up for survival after this time point. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |